<DOC>
	<DOCNO>NCT01527006</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics , efficacy , safety perampanel oral suspension seizure frequency pediatric participant maintain one three stable antiepileptic drug</brief_summary>
	<brief_title>Pharmacokinetics , Efficacy , Safety Perampanel Oral Suspension Seizure Frequency Pediatric Subjects Maintained One Three Stable Antiepileptic Drugs</brief_title>
	<detailed_description>This multicenter , multiple ascend dose , open-label study ( Core Study ) Extension Phase . The Core Study consist 2 phase , Pretreatment Phase Treatment Phase . The Pretreatment Phase last 2 week duration , participant assess eligibility participate study . The Treatment Phase consist 3 period : Titration ( 7 week ) , Maintenance ( 4 week ) , Follow-up ( 4 week ; participant roll Extension Phase complete Treatment Phase participant discontinue study ) . All subject complete scheduled visit include final visit Treatment Phase ( Core Study ) eligible participate Extension Phase study . The Extension Phase consist 2 period : Maintenance ( 41 week ) Follow-up ( 4 week ) .</detailed_description>
	<criteria>Inclusion : 1 . Have minimum weight 10 kg ( 22 lb ) 2 . Have brain imaging ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) prior Visit 1 rule progressive cause epilepsy 3 . Have diagnosis epilepsy type seizure accord International League Against Epilepsy 's ( ILAE ) Classification Epileptic Seizures ( 1981 ) . Diagnosis establish least 6 month prior Visit 1 , clinical history electroencephalogram ( EEG ) consistent epilepsy ; normal interictal EEGs allow provide participant meet diagnosis criterion ( i.e . clinical history ) 4 . Have one seizure ( ) 4 week prior Visit 1 5 . Are currently treat stable dos one maximum three AEDs least 4 week prior Visit 1 throughout study duration ( Only one perampanel induce AED [ i.e . carbamazepine , oxcarbazepine , phenytoin ] maximum 3 AEDs allow least one third participant age cohort exceed one half population age cohort . The remain participant take inducer ) 6 . Have current concomitant AED regimen 2 month stable dose least 4 week prior Visit 1 7 . Must discontinue restricted medication least 2 week five halflives ( whichever longer ) prior Visit 1 8 . Females age least 8 year childbearing potential must negative serum betahCG Visit 1 negative urine pregnancy test prior titration Visit 2 . Female participant childbearing potential must agree duration study period least 60 day follow administration last dose study drug abstinent commit consistent correct use medically acceptable method birth control ( e.g. , doublebarrier method [ condom + spermicide , condom + diaphragm spermicide ] ) Exclusion : 1 . Have history status epilepticus require hospitalization 6 month prior Visit 1 2 . Have current history pseudoseizures ( psychogenic nonepileptic seizure [ PNES ] ) birth within approximately 5 year prior Visit 1 3 . Have seizure due treatable medical condition , arise due metabolic disturbance , toxic exposure , active infection 4 . Have epilepsy secondary progressive cerebral disease progressive neurodegenerative disease 5 . Have epilepsy surgery within 1 year prior Visit 1 6 . Are scheduled and/or confirm epilepsy surgery within 6 month Visit 1 ; however , previously document fail epilepsy surgery allow 7 . Use intermittent rescue benzodiazepine ( i.e . 12 dos 24hour period consider onetime rescue ) two time 30day period prior Visit 1 8 . If felbamate use concomitant AED , participant must felbamate least 2 year , stable dose 8 week prior Visit 1 . They must history white blood cell ( WBC ) count 2500/L ( 2.50 x 10^9/L ) , platelets 100,000 , liver function test ( LFTs ) 3 time upper limit normal ( ULN ) , indication hepatic bone marrow dysfunction receive felbamate . If participant receive felbamate past , must discontinue 8 week prior Visit 1 9 . Have concomitant use vigabatrin : participant take vigabatrin past must vigabatrin approximately 5 month prior Visit 1 must documentation show evidence vigabatrinassociated clinically significant abnormality visual perimetry test 10 . If ketogenic diet use , participant must stable regimen least 4 week prior Visit 1 11 . Have previously participate clinical trial involve perampanel</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>